EBS - Is Emergent BioSolutions the Next Hot Coronavirus Stock?
When it comes to hot coronavirus stocks, investors have likely heard a lot about the many potential vaccines and other treatments currently being developed. However, there is one company working in the COVID-19 vaccine market that hasn't gotten much attention in comparison with some of its peers.
That business is Emergent BioSolutions (NYSE: EBS), a biotech company that specializes in developing vaccines and antibody therapies. The company recently ended up grabbing quite a bit of investor attention thanks to a recently announced partnership with Johnson & Johnson (NYSE: JNJ) to help manufacture the latter's COVID-19 vaccine.
Nor is this the first COVID-19-related deal that Emergent has signed. Over the past month, the company has signed agreements with a number of other COVID-19 vaccine makers as well. Does all this make Emergent BioSolutions the next hot coronavirus stock, one you should keep on your watch list?